{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:45:49Z","timestamp":1787499949453,"version":"build-2736575974"},"reference-count":54,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T00:00:00Z","timestamp":1735257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Under standard therapies, the incidence of drug-induced liver injury (DILI) in patients with tuberculosis ranges from 2% to 28%. Numerous studies have identified the risk factors for antituberculosis DILI; however, none have been conducted in a multiethnic real-world setting. The primary outcome of the current study was to identify the risk factors that could be used as the best predictors of DILI in a multiethnic cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A nested case-control study was conducted in patients at the tuberculosis clinic of Luigi Sacco Hospital in Milan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study included 102 patients (mean age [SD], 45.6 [15.6] years). For each patient with hepatotoxicity, 2 controls were matched for sex, age, body mass index, tuberculosis\/tuberculosis infection diagnosis, and index date. We found that N-acetyltransferase 2 gene (NAT2) slow acetylator status was the best independent predictor of DILI (odds ratio, 5.97 [95% confidence interval, 1.38\u201325.76]; P = .02].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>NAT2 genotype\u2013guided dosing may help optimize antituberculosis drug treatment and prevent treatment failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trials Registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov NCT06539455<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciae583","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T07:35:18Z","timestamp":1734075318000},"page":"145-152","source":"Crossref","is-referenced-by-count":5,"title":["<i>NAT2<\/i>\n                    Slow Acetylator Phenotype as a Significant Risk Factor for Hepatotoxicity Caused by Antituberculosis Drugs: Results From a Multiethnic Nested Case-Control Study"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2837-5248","authenticated-orcid":false,"given":"Stefania","family":"Cheli","sequence":"first","affiliation":[{"name":"ICPS, Pharmacovigilance & Clinical Research, Department of Biomedical and Clinical Sciences, ASST Fatebenefratelli Sacco, University Hospital Luigi Sacco, Universit\u00e0 Degli Studi di Milano , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Torre","sequence":"additional","affiliation":[{"name":"III Infectious Disease Unit, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Schiuma","sequence":"additional","affiliation":[{"name":"II Infectious Disease Unit, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8276-3663","authenticated-orcid":false,"given":"Cristina","family":"Montrasio","sequence":"additional","affiliation":[{"name":"Center of Functional Genomics and Rare Diseases, Buzzi Children's Hospital , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9750-5627","authenticated-orcid":false,"given":"Aurora","family":"Civati","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Clinical Sciences, Universit\u00e0 Degli Studi di Milano , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Galimberti","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Clinical Sciences, Universit\u00e0 Degli Studi di Milano , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3513-9593","authenticated-orcid":false,"given":"Vera","family":"Battini","sequence":"additional","affiliation":[{"name":"ICPS, Pharmacovigilance & Clinical Research, Department of Biomedical and Clinical Sciences, ASST Fatebenefratelli Sacco, University Hospital Luigi Sacco, Universit\u00e0 Degli Studi di Milano , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4197-6543","authenticated-orcid":false,"given":"Ilaria","family":"Mariani","sequence":"additional","affiliation":[{"name":"ICPS, Pharmacovigilance & Clinical Research, Department of Biomedical and Clinical Sciences, ASST Fatebenefratelli Sacco, University Hospital Luigi Sacco, Universit\u00e0 Degli Studi di Milano , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5162-4751","authenticated-orcid":false,"given":"Giulia","family":"Mosini","sequence":"additional","affiliation":[{"name":"ICPS, Pharmacovigilance & Clinical Research, Department of Biomedical and Clinical Sciences, ASST Fatebenefratelli Sacco, University Hospital Luigi Sacco, Universit\u00e0 Degli Studi di Milano , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4107-196X","authenticated-orcid":false,"given":"Carla","family":"Carnovale","sequence":"additional","affiliation":[{"name":"ICPS, Pharmacovigilance & Clinical Research, Department of Biomedical and Clinical Sciences, ASST Fatebenefratelli Sacco, University Hospital Luigi Sacco, Universit\u00e0 Degli Studi di Milano , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9186-1185","authenticated-orcid":false,"given":"Sonia","family":"Radice","sequence":"additional","affiliation":[{"name":"ICPS, Pharmacovigilance & Clinical Research, Department of Biomedical and Clinical Sciences, ASST Fatebenefratelli Sacco, University Hospital Luigi Sacco, Universit\u00e0 Degli Studi di Milano , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7333-8270","authenticated-orcid":false,"given":"Emilio","family":"Clementi","sequence":"additional","affiliation":[{"name":"ICPS, Pharmacovigilance & Clinical Research, Department of Biomedical and Clinical Sciences, ASST Fatebenefratelli Sacco, University Hospital Luigi Sacco, Universit\u00e0 Degli Studi di Milano , Milan ,","place":["Italy"]},{"name":"Scientific Institute, IRCCS E. Medea , Bosisio Parini, LC ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gori","sequence":"additional","affiliation":[{"name":"II Infectious Disease Unit, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital , Milan ,","place":["Italy"]},{"name":"Department of Biomedical and Clinical Sciences, Universit\u00e0 Degli Studi di Milano , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0569-9407","authenticated-orcid":false,"given":"Spinello","family":"Antinori","sequence":"additional","affiliation":[{"name":"III Infectious Disease Unit, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital , Milan ,","place":["Italy"]},{"name":"Department of Biomedical and Clinical Sciences, Universit\u00e0 Degli Studi di Milano , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,27]]},"reference":[{"key":"2025080104322250700_ciae583-B1","volume-title":"Global tuberculosis report 2023","author":"World Health Organization","year":"2023"},{"key":"2025080104322250700_ciae583-B2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1093\/trstmh\/trv108","article-title":"The WH\u2019's new end TB strategy in the post-2015 era of the sustainable development goals","volume":"110","author":"L\u00f6nnroth","year":"2016","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2025080104322250700_ciae583-B3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jceh.2012.12.001","article-title":"Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management","volume":"3","author":"Ramappa","year":"2013","journal-title":"J Clin Exp Hepatol"},{"key":"2025080104322250700_ciae583-B4","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1440-1746.2007.05207.x","article-title":"Antituberculosis drug-induced hepatotoxicity: concise up-to-date review","volume":"23","author":"Tostmann","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"2025080104322250700_ciae583-B5","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.medmal.2006.12.006","article-title":"Les effets ind\u00e9sirables des antituberculeux: \u00e9pid\u00e9miologie, m\u00e9canismes et conduite \u00e0 tenir [Adverse effects of antitubercular drugs: epidemiology, mechanisms, and patient management]","volume":"37","author":"Aouam","year":"2007","journal-title":"Med Mal Infect"},{"key":"2025080104322250700_ciae583-B6","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3346\/jkms.2015.30.2.167","article-title":"Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels","volume":"30","author":"Jeong","year":"2015","journal-title":"J Korean Med Sci"},{"key":"2025080104322250700_ciae583-B7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0377-1237(06)80155-3","article-title":"Risk factors of hepatotoxicity during anti-tuberculosis treatment","volume":"62","author":"Anand","year":"2006","journal-title":"Med J Armed Forces India"},{"key":"2025080104322250700_ciae583-B8","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41572-019-0105-0","article-title":"Drug-induced liver injury","volume":"5","author":"Andrade","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"2025080104322250700_ciae583-B9","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1111\/liv.15262","article-title":"Incidence and risk factors of drug-induced liver injury","volume":"42","author":"Li","year":"2022","journal-title":"Liver Int"},{"key":"2025080104322250700_ciae583-B10","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/thx.51.2.132","article-title":"Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study","volume":"51","author":"Pande","year":"1996","journal-title":"Thorax"},{"key":"2025080104322250700_ciae583-B11","first-page":"995","article-title":"Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics","volume":"6","author":"Lee","year":"2002","journal-title":"Int J Tuberc Lung Dis"},{"key":"2025080104322250700_ciae583-B12","first-page":"81","article-title":"Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity","volume":"132","author":"Singla","year":"2010","journal-title":"Indian J Med Res"},{"key":"2025080104322250700_ciae583-B13","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jinf.2011.04.005","article-title":"Risk factors of hepatitis during anti-tuberculous treatment and implications of hepatitis virus load","volume":"62","author":"Wang","year":"2011","journal-title":"J Infect"},{"key":"2025080104322250700_ciae583-B14","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/01.qai.0000152400.36723.85","article-title":"Factors that complicate the treatment of tuberculosis in HIV-infected patients","volume":"39","author":"Dworkin","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025080104322250700_ciae583-B15","first-page":"1499","article-title":"The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity","volume":"8","author":"Fern\u00e1ndez-Villar","year":"2004","journal-title":"Int J Tuberc Lung Dis"},{"key":"2025080104322250700_ciae583-B16","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.apsb.2016.07.014","article-title":"Isoniazid metabolism and hepatotoxicity","volume":"6","author":"Wang","year":"2016","journal-title":"Acta Pharm Sin B"},{"key":"2025080104322250700_ciae583-B17","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/cpt.2100","article-title":"Genetic risk factors in drug-induced liver injury due to isoniazid-containing antituberculosis drug regimens","volume":"109","author":"Nicoletti","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"2025080104322250700_ciae583-B18","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1124\/dmd.121.000389","article-title":"Metabolism and hepatotoxicity of pyrazinamide, an antituberculosis drug","volume":"49","author":"Hussain","year":"2021","journal-title":"Drug Metab Dispos"},{"key":"2025080104322250700_ciae583-B19","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s00228-012-1429-9","article-title":"NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy","volume":"69","author":"Azuma","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"2025080104322250700_ciae583-B20","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1111\/jgh.12194","article-title":"Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in western India","volume":"28","author":"Gupta","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"2025080104322250700_ciae583-B21","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.2217\/pgs-2019-0131","article-title":"NAT2 slow acetylator is associated with anti-tuberculosis drug-induced liver injury severity in Indonesian population","volume":"20","author":"Yuliwulandari","year":"2019","journal-title":"Pharmacogenomics"},{"key":"2025080104322250700_ciae583-B22","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5588\/ijtld.15.0310","article-title":"NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in Thai patients","volume":"20","author":"Wattanapokayakit","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"key":"2025080104322250700_ciae583-B23","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.patbio.2011.07.001","article-title":"Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis","volume":"60","author":"Ben Mahmoud","year":"2012","journal-title":"Pathol Biol (Paris)"},{"key":"2025080104322250700_ciae583-B24","doi-asserted-by":"crossref","first-page":"499","DOI":"10.5588\/ijtld.12.0645","article-title":"N-acetyl transferase 2 and cytochrome P450 2E1 genes and isoniazid-induced hepatotoxicity in Brazilian patients","volume":"17","author":"Santos","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"key":"2025080104322250700_ciae583-B25","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1186\/s12864-016-3078-3","article-title":"Genome-wide association and replication study of anti-tuberculosis drugs-induced liver toxicity","volume":"17","author":"Petros","year":"2016","journal-title":"BMC Genomics"},{"key":"2025080104322250700_ciae583-B26","doi-asserted-by":"crossref","first-page":"BSR20180845","DOI":"10.1042\/BSR20180845","article-title":"Pharmacogenetic association between NAT2 gene polymorphisms and isoniazid induced hepatotoxicity: trial sequence meta-analysis as evidence","volume":"39","author":"Khan","year":"2019","journal-title":"Biosci Rep"},{"key":"2025080104322250700_ciae583-B27","first-page":"474","article-title":"Association of cytochrome P450 2E1 and N-acetyltransferase 2 genotypes with serum isoniazid level and anti-tuberculosis drug-induced hepatotoxicity: a cross-sectional study","volume":"48","author":"Pourmohamadi","year":"2023","journal-title":"Iran J Med Sci"},{"key":"2025080104322250700_ciae583-B28","author":"National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health. National Institute on Alcohol Abuse and Alcoholism website","year":"2024-10"},{"key":"2025080104322250700_ciae583-B29","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1164\/rccm.202309-1583OC","article-title":"A nanopore sequencing-based pharmacogenomic panel to personalize tuberculosis drug dosing","volume":"209","author":"Verma","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2025080104322250700_ciae583-B30","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1164\/rccm.202103-0564OC","article-title":"A rapid pharmacogenomic assay to detect NAT2 polymorphisms and guide isoniazid dosing for tuberculosis treatment","volume":"204","author":"Verma","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2025080104322250700_ciae583-B31","doi-asserted-by":"crossref","first-page":"1171353","DOI":"10.3389\/fphar.2023.1171353","article-title":"N-acetyltransferase 2 genetic polymorphisms and anti-tuberculosis-drug-induced liver injury: a correlation study","volume":"14","author":"Cheng","year":"2023","journal-title":"Front Pharmacol"},{"key":"2025080104322250700_ciae583-B32","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2217\/pgs-2022-0022","article-title":"NAT2 polymorphism and clinical factors that increase antituberculosis drug-induced hepatotoxicity","volume":"23","author":"Mohamed Noor","year":"2022","journal-title":"Pharmacogenomics"},{"key":"2025080104322250700_ciae583-B33","doi-asserted-by":"crossref","first-page":"293","DOI":"10.5588\/ijtld.18.0324","article-title":"NAT2 variants and toxicity related to anti-tuberculosis agents: a systematic review and meta-analysis","volume":"23","author":"Richardson","year":"2019","journal-title":"Int J Tuberc Lung Dis"},{"key":"2025080104322250700_ciae583-B34","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1111\/bcp.13722","article-title":"The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis","volume":"84","author":"Zhang","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"2025080104322250700_ciae583-B35","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00228-006-0111-5","article-title":"CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis","volume":"62","author":"Vuilleumier","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"2025080104322250700_ciae583-B36","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.5588\/ijtld.10.0648","article-title":"N-acetyltransferase 2 polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity in Caucasians","volume":"15","author":"Leiro-Fernandez","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"key":"2025080104322250700_ciae583-B37","first-page":"81","article-title":"Determining the relation between N-acetyltransferase-2 acetylator phenotype and antituberculosis drug induced hepatitis by molecular biologic tests","volume":"56","author":"Bozok Cetinta\u015f","year":"2008","journal-title":"Tuberk Toraks"},{"key":"2025080104322250700_ciae583-B38","doi-asserted-by":"crossref","first-page":"790","DOI":"10.3390\/jpm12050790","article-title":"Clinical and genetic risk factors for drug-induced liver injury associated with anti-tuberculosis treatment\u2014a study from patients of Portuguese health centers","volume":"12","author":"Cavaco","year":"2022","journal-title":"J Pers Med"},{"key":"2025080104322250700_ciae583-B39","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/FPC.0000000000000339","article-title":"NAT2 ultra-slow acetylator and risk of anti-tuberculosis drug-induced liver injury: a genotype-based meta-analysis","volume":"28","author":"Suvichapanich","year":"2018","journal-title":"Pharmacogenet Genomics"},{"key":"2025080104322250700_ciae583-B40","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/17512433.2024.2311314","article-title":"Influence of N-acetyltransferase 2 polymorphisms and clinical variables on liver function profile of tuberculosis patients","volume":"17","author":"Thomas","year":"2024","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2025080104322250700_ciae583-B41","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1590\/S0074-02762011000600011","article-title":"Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients","volume":"106","author":"Teixeira","year":"2011","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"2025080104322250700_ciae583-B42","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/j.1365-2710.2012.01334.x","article-title":"CYP2E1, GSTM1 and GSTT1 genetic polymorphisms and susceptibility to antituberculosis drug-induced hepatotoxicity: a nested case-control study","volume":"37","author":"Tang","year":"2012","journal-title":"J Clin Pharm Ther"},{"key":"2025080104322250700_ciae583-B43","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1053\/jhep.2003.50144","article-title":"Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis","volume":"37","author":"Huang","year":"2003","journal-title":"Hepatology"},{"key":"2025080104322250700_ciae583-B44","author":"AIFA Medicines"},{"key":"2025080104322250700_ciae583-B45","author":"Clinical Pharmacogenetics Implementation Consortium (CPIC)"},{"key":"2025080104322250700_ciae583-B46","first-page":"49","article-title":"Tuberculosis drug-induced liver injury","volume":"6","author":"Soedarsono","year":"2020","journal-title":"J Respir"},{"key":"2025080104322250700_ciae583-B47","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1080\/19390211.2018.1472165","article-title":"Malnutrition and associated disorders in tuberculosis and its therapy","volume":"16","author":"Martin","year":"2019","journal-title":"J Diet Suppl"},{"key":"2025080104322250700_ciae583-B48","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/hep.22895","article-title":"Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex","volume":"49","author":"Lucena","year":"2009","journal-title":"Hepatology"},{"key":"2025080104322250700_ciae583-B49","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1345\/aph.1D525","article-title":"Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors","volume":"38","author":"Shakya","year":"2004","journal-title":"Ann Pharmacother"},{"key":"2025080104322250700_ciae583-B50","doi-asserted-by":"crossref","first-page":"1700216","DOI":"10.1183\/13993003.00216-2017","article-title":"Alcohol consumption as a risk factor for tuberculosis: meta-analyses and burden of disease","volume":"50","author":"Imtiaz","year":"2017","journal-title":"Eur Respir J"},{"key":"2025080104322250700_ciae583-B51","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1164\/rccm.200206-626OC","article-title":"Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis","volume":"167","author":"Yee","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"2025080104322250700_ciae583-B52","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1183\/09031936.00090306","article-title":"Standard anti-tuberculosis treatment and hepatotoxicity: do dosing schedules matter?","volume":"29","author":"Chang","year":"2007","journal-title":"Eur Respir J"},{"key":"2025080104322250700_ciae583-B53","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/1471-2458-9-450","article-title":"The association between alcohol use, alcohol use disorders and tuberculosis (TB): a systematic review","volume":"9","author":"Rehm","year":"2009","journal-title":"BMC Public Health"},{"key":"2025080104322250700_ciae583-B54","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1093\/cid\/ciz1212","article-title":"Cost-effectiveness of a pharmacogenomic test for stratified isoniazid dosing in treatment of active Tuberculosis","volume":"71","author":"Rens","year":"2020","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciae583\/61284596\/ciae583.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/1\/145\/61284596\/ciae583.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/1\/145\/61284596\/ciae583.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T08:33:16Z","timestamp":1754037196000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/81\/1\/145\/7933644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,27]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12,27]]},"published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciae583","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7,15]]},"published":{"date-parts":[[2024,12,27]]}}}